SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: majormember who wrote (599)6/15/1998 4:47:00 PM
From: Jim Mac  Read Replies (1) of 1754
 
Yes, Sunrise looks very promising.

But Sunrise IS competing with Visx for hyperopia patients. Visx will likely get FDA approval in late 1998, and since most U.S. LVC procedures are done on Visx systems (over 200 Visx systems in U.S. now), you'll see hyperopia's being done on Visx lasers in 1999 or late 98.

Excimers probably will offer the greatest range of hyperopia corrections due to the nature of the procedure, although most hyperopes fall under Sunrise's capabilities also. And Sunrise is much cheaper to acquire and use, and is more patient-friendly than HPRK and H-LASIK.

But Sunrise must demonstrate LT stability, which excimers generally have already done.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News